Unión Europea - español - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artritis, reumatoide - inmunosupresores - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Uruguay - español - Ministerio de Salud (Dirección Oficina Central)

abbvie - comprimido recubierto de liberación prolongada - upadacitinib 15 mg comprimido de liberación modificada

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

abbvie sas, sucursal del peru - droguerÍa - tableta de liberacion prolongada - por tableta - - upadacitinib

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

abbvie sas, sucursal del peru - droguerÍa - tableta de liberacion prolongada - por vial - - upadacitinib

Uruguay - español - Ministerio de Salud (Dirección Oficina Central)

abbvie - comprimido recubierto de liberación prolongada - upadacitinib 30 mg comprimido de liberación modificada

Uruguay - español - Ministerio de Salud (Dirección Oficina Central)

abbvie - comprimido recubierto - upadacitinib 45 mg comprimido de liberación modificada

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

abbvie sas, sucursal del peru - droguerÍa - tableta de liberacion prolongada - por tableta - - upadacitinib

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

abbvie inc. estados unidos - cantidad por cada tableta: upadacitinib hemihidrato 15.4 mg b b. correspondiente con 15 mg de upadacitinib en base anhidra. - tableta recubierta con pelicula de liberacion prolongada - cantidad por cada tableta: upadacitinib hemihidrato 15.4 mg b b. correspondiente con 15 mg de upadacitinib en base anhidra.

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

abbvie deutschland gmbh & co. kg alemania - cantidad por cada comprimido upadacitinib hemihidrato 30.7 mg a a. correspondiente a 30 mg de upadacitinib en base anhidra - comprimido recubierto con pelicula de liberacion prolongada - cantidad por cada comprimido upadacitinib hemihidrato 30.7 mg a a. correspondiente a 30 mg de upadacitinib en base anhidra

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

abbvie deutschland gmbh & co. kg alemania - cantidad por tableta: upadacitinib hemihidratado 46.1 a a. corresponde a 45 mg de upadacitinib base anhidra. - tableta recubierta de liberacion prolongada - cantidad por tableta: upadacitinib hemihidratado 46.1 a a. corresponde a 45 mg de upadacitinib base anhidra.